Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HALO

Halozyme Therapeutics Inc

Sep 12 • 04:00PM ET

76.90

-0.63 -0.81 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB XBI VBK VXF MDY IWP XMHQ IBB

Scroll to Statements

Index	-	P/E	17.57	EPS (ttm)	4.38	Insider Own	1.10%	Shs Outstand	117.62M	Perf Week	2.63%
Market Cap	8.99B	Forward P/E	9.65	EPS next Y	7.97	Insider Trans	-17.29%	Shs Float	115.68M	Perf Month	18.07%
Enterprise Value	9.96B	PEG	0.54	EPS next Q	1.63	Inst Own	100.67%	Short Float	10.27%	Perf Quarter	41.00%
Income	557.28M	P/S	7.63	EPS this Y	45.74%	Inst Trans	-4.35%	Short Ratio	5.41	Perf Half Y	25.94%
Sales	1.18B	P/B	27.18	EPS next Y	29.21%	ROA	27.70%	Short Interest	11.88M	Perf YTD	60.85%
Book/sh	2.83	P/C	16.41	EPS next 5Y	32.26%	ROE	179.14%	52W High	77.58 -0.88%	Perf Year	29.77%
Cash/sh	4.69	P/FCF	16.64	EPS past 3/5Y	7.74% -	ROIC	30.26%	52W Low	42.01 83.05%	Perf 3Y	95.13%
Dividend Est.	-	EV/EBITDA	13.02	Sales past 3/5Y	31.82% 38.95%	Gross Margin	78.17%	Volatility	2.16% 2.27%	Perf 5Y	177.62%
Dividend TTM	-	EV/Sales	8.45	EPS Y/Y TTM	71.10%	Oper. Margin	57.92%	ATR (14)	1.69	Perf 10Y	356.38%
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	34.97%	Profit Margin	47.28%	RSI (14)	77.93	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.36	EPS Q/Q	84.34%	SMA20	5.08%	Beta	1.17	Target Price	70.56
Payout	0.00%	Debt/Eq	4.54	Sales Q/Q	40.79%	SMA50	18.81%	Rel Volume	0.51	Prev Close	77.53
Employees	350	LT Debt/Eq	4.54	Earnings	Aug 05 AMC	SMA200	32.52%	Avg Volume	2.20M	Price	76.90
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.76% 13.92%	Trades		Volume	1,120,990	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48

Show Previous Ratings

Sep-09-25 09:55AM	5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts (Zacks)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
09:42AM	Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion (Zacks)
Sep-05-25 10:17AM	Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings (Zacks)
09:08AM	Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns (Zacks)
10:51AM	Loading…
Sep-04-25 10:51AM	4 PEG-Rated GARP Stocks That Offer Both Value and Growth (Zacks)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
12:00PM	Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice (Zacks)
10:00AM	Best Momentum Stock to Buy for September 3rd (Zacks)
09:40AM	Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? (Zacks)
09:15AM	Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:00AM	How to Find Strong Buy Medical Stocks Using the Zacks Rank (Zacks)
06:23AM	New Strong Buy Stocks for September 3rd (Zacks)
Sep-02-25 08:30AM	Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today (Zacks)
Aug-29-25 04:52AM	Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand (Insider Monkey)
12:26AM	Loading…
12:26AM	Morgan Stanley Raises PT on Halozyme Therapeutics (HALO) to $80 From $75 (Insider Monkey)
Aug-28-25 11:50PM	Morgan Stanley Raises PT on Halozyme Therapeutics (HALO), After Q2 Results (Insider Monkey)
08:30AM	Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Aug-26-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-25-25 08:58AM	Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance (Insider Monkey)
Aug-22-25 08:05AM	Biotech Leader Rallies To Highs As Funds Load Up (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-12-25 09:10AM	H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 (Insider Monkey)
Aug-11-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-08-25 09:55AM	After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright (Zacks)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-06-25 11:57AM	HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
03:27AM	Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:00PM	Loading…
Aug-05-25 07:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
06:05PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS (PR Newswire)
Aug-04-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-29-25 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-28-25 02:07AM	Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT (Insider Monkey)
Jul-23-25 11:36AM	European Commission Approved DARZALEX Faspro for Adult Patients with Smouldering Multiple Myeloma (PR Newswire)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-22-25 12:10PM	Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again (Zacks)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
08:50AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Halozyme to Report Second Quarter 2025 Financial and Operating Results (PR Newswire)
Jul-16-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jul-04-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-03-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jun-30-25 04:05PM	Halozyme Therapeutics Added to Russell 1000 Index (PR Newswire)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Jun-20-25 01:15PM	Halozyme Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jun-17-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-16-25 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Jun-13-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-05-25 11:30AM	Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? (Zacks)
Jun-04-25 08:55AM	PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo (TipRanks)
08:50AM	Merck granted review of Halozyme patent claims by PTAB (TipRanks)
05:08AM	Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme (Zacks)
Jun-03-25 10:45AM	4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025 (Zacks)
May-29-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-28-25 04:05PM	Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
10:15AM	Implied Volatility Surging for Halozyme Therapeutics Stock Options (Zacks)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
08:30AM	Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo (nivolumab) Co-Formulated with ENHANZE Across Multiple Solid Tumor Indications (PR Newswire)
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-23-25 10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +6.27%
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
05:41AM	Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
11:23AM	4 Stocks With Impressive Interest Coverage Ratio to Buy Now (Zacks)
11:00AM	Halozyme, J&J slide as analyst cuts rating on CMS draft guidance (TipRanks)
08:27AM	Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday (Insider Monkey)
May-13-25 04:18PM	Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News (Investor's Business Daily) -24.56%
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
May-12-25 03:49PM	Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now? (Insider Monkey)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-10-25 11:47AM	S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points (Investor's Business Daily)
May-09-25 12:00PM	Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? (Zacks)
10:36AM	Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
01:47AM	Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 12:13PM	HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View (Zacks) +18.12%
03:19AM	Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 07:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS (PR Newswire)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM
Henderson Jeffrey William	Director	Feb 03 '25	Sale	56.30	5,000	281,517	38,611	Feb 04 06:07 PM
JEFFREY HENDERSON	Director	Feb 03 '25	Proposed Sale	56.64	15,000	849,600		Feb 03 04:21 PM
Henderson Jeffrey William	Director	Jan 06 '25	Sale	50.01	10,000	500,060	43,611	Jan 07 04:14 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '25	Option Exercise	0.00	7,611	0	19,291	Jan 06 05:12 PM
JEFFREY HENDERSON	Director	Jan 06 '25	Proposed Sale	47.74	10,000	477,400		Jan 06 04:26 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your FINVIZ experience